復星醫藥(02196.HK)稱無理由認為mRNA疫苗相關批次產品安全可能存在風險
格隆匯3月24日丨復星醫藥(02196.HK)發佈公吿,於2021年3月24日,有媒體轉載中國香港、澳門政府新聞,因BioNTech生產的mRNA新冠疫苗西林瓶封蓋有關瑕疵,港澳地區今日起暫停接種。
截至本公吿日,香港及澳門己獲供應的mRNA新冠疫苗BNT162b2共有210102、210104兩個批次。
2021年3月23日晚間接BioNTech書面通知,BioNTech注意到其生產供應香港和澳門的批號為210102的該疫苗產品中存在少量西林瓶封蓋有關的瑕疵。本着對產品安全高度負責的態度,為確保疫苗的接種安全, BioNTech和集團已發起對該問題的原因調查,並已於2021年3月24日通知香港及澳門相關主管部門暫停接種批號為210102的該疫苗,直至調查結束。此外,出於審慎考慮,用於供應香港的批號為210104的該疫苗產品也將進行封存,不再發送至任何接種站或接種點,直至另行通知。
截至本公吿日,並無理由認為相關批次產品安全可能存在風險,具體情況以最終調查結果為準。該疫苗本次暫停使用並做封存,對於相關批次疫苗在香港、澳門的後續接種安排可能存在影響,具體以調查結果為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.